Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. Issue 51 (December 2017)

• Record Type: Journal Article
• Authors: Anzai, Masaki; Morikawa, Miwa; Okuno, Takehiro; Umeda, Yukihiro; Demura, Yoshiki; Sonoda, Tomoaki; Yamaguchi, Makiko; Kanno, Kiyoshi; Shiozaki, Kohei; Ameshima, Shingo; Akai, Masaya; Ishizuka, Tamotsu
• Other Names: Liu. Yang section editor.
• Is Part Of: Medicine. Volume 96:Issue 51(2017)
• Publication Date: 2017-12
• Subjects: nab-paclitaxel -- non-small cell lung cancer -- previously treated patients -- second-line chemotherapy; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000009320
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC). Methods: A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled. Nab-PTX was administered intravenously at a dose of 100 mg/m 2 on days 1, 8, and 15 of a 28-day cycle. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and toxicity profile were evaluated. Results: The ORR was 28.1%, the DCR was 71.9%, median PFS was 3.9 months (95% confidence interval [CI] 2.7–5.1 months), and median OS was 10.9 months (95% CI 9.5–12.3 months). The mean relative dose intensity of nab-PTX was 77%. Grade 3 or 4 neutropenia, and grade 3 febrile neutropenia were observed in 11 and 1 of 32 patients, respectively. As nonhematologic toxicities, grade 3 peripheral sensory neuropathy and pneumonitis were each observed in 2 of 32 patients. Conclusion: Nab-PTX is an active and well-tolerated regimen in patients with previously treated NSCLC.